Abselion’s VP of Science, Paolo Romele, has contributed to a multi-contributor editorial published by BioCompare, exploring the role of cell line selection in therapeutic antibody production.
The article brings together perspectives from across the bioprocessing community to discuss how different cell line platforms influence productivity, quality, and scalability. Paolo’s contribution draws on his experience supporting early-stage antibody screening and protein quantification during cell line development.
Read the full article here.